These 10 large-cap stocks gained this week, some due to positive news such as media rights deals or FDA approvals.

Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.

Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate ...

First FDA-approved therapy for non-cystic fibrosis bronchiectasis; addresses a major unmet respiratory need. 2. Phase 3 data ...

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a ...

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

Devarakonda covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Scholar Rock Holding, and Incyte. According to TipRanks, Devarakonda has an average return of -2.8% and a 37.04 ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...

H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...

Jefferies analyst Kelly Shi maintained a Buy rating on Insmed today and set a price target of $148.00. The company’s shares closed today at $122.00. Elevate Your Investing Strat ...

The Clean Label Project tested store-bought coffee and found it is mostly free of harmful levels of toxins and contaminants, ...